MQM sends $10m defamation notice to NYT journalist

Published
48

KARACHI: The Muttahida Qaumi Movement (MQM) issued a 10-million-dollar defamation notice to The New York Times' former Islamabad bureau chief, Declan Walsh, and the editor, printer and publisher of the newspaper for allegedly causing disrepute to Altaf Hussain in a 'baseless' report published, according to the official website of the MQM.

The notice was served by MQM's counsel Barrister Farogh Naseem which stated that the baseless reporting on behalf of the NYT had caused damage to the repute of MQM chief Altaf Hussain.

The legal notice asked the New York Times newspaper editor, it's printer, publisher and journalist Declan Walsh to tender an un-conditional apology within seven days and warned of due legal action in case of failure to do so.

It is pertinent to note here that Declan Walsh, The New York Times' then Islamabad bureau chief, was expelled from Pakistan on the eve of May 2013 general elections, after the interim government had accused him of unspecified ''undesirable activities.''

Opinion

Editorial

Nuclear uncertainty
Updated 23 Oct, 2026

Nuclear uncertainty

With matters frozen in the political and diplomatic spheres, it will take military-to-military engagement to prevent miscalculation in the strategic sphere.
Auto illusion
23 Oct, 2026

Auto illusion

PAKISTAN’S draft auto policy 2026-31 is ambitious in its targets and directionless in its strategy. It promises...
Two crimes
23 Oct, 2026

Two crimes

THE senseless killing of a teenager by his employers in Multan is a crime that deserves unqualified condemnation. It...
Makkah pact clarity
Updated 22 Oct, 2026

Makkah pact clarity

Fresh aggression can kick off a firestorm that will be in no one’s control, hence it is best to abandon such reckless plans.
Common ground
Updated 22 Oct, 2026

Common ground

Regrettably, the two sides still fail to see the country’s economic, security, and governance crises as challenges that must be solved politically.
The treatment gap
22 Oct, 2026

The treatment gap

A BREAST cancer diagnosis no longer carries the bleak outlook it did a generation ago. Targeted medicines,...